Dev R. Mehrotra

Dev R. Mehrotra

Auto-generated profile, based on publicly available information

Dev R. Mehrotra

College of Engineering, Boston University, Boston, MA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2025 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
MKMasumeh Kazemi
Masumeh Kazemi
CYChenhao Yu
Chenhao Yu
DMDev R. Mehrotra
Dev R. Mehrotra
EEErik E. Ersland
Erik E. Ersland
SZStefan Zbyn
Stefan Zbyn
MAMichael B. Albro
Michael B. Albro

15 December 2025 in Acta Biomaterialia
Verified
Journal Article
Closed access
CDChristian D. DeMoya
Christian D. DeMoya
PHPierson Husted
Pierson Husted
DMDev R. Mehrotra
Dev R. Mehrotra
MAMichael B. Albro
Michael B. Albro
BSBrian D. Snyder
Brian D. Snyder
MGMark Grinstaff
Mark Grinstaff

17 June 2026 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
MGMason J. Garcia
Mason J. Garcia
DMDev R. Mehrotra
Dev R. Mehrotra
JGJake Giering
Jake Giering
EEErik E. Ersland
Erik E. Ersland
ALAlberto Lalli
Alberto Lalli
ANAra Nazarian
Ara Nazarian

15 October 2026 in Osteoarthritis and Cartilage
Verified
Journal Article
Open access
NRNereida J. Ramirez
Nereida J. Ramirez
CSCatrina J. Silveira
Catrina J. Silveira
RLRaine Lunde-Young
Raine Lunde-Young
SHShannon Huggins
Shannon Huggins
JGJacob J. Giering
Jacob J. Giering
ACApril M. Craft
April M. Craft
Progressive Pseudorheumatoid Arthropathy of Childhood (PPAC), also known as Progressive Pseudorheumatoid Dysplasia (PPRD), is an autosomal recessive disorder caused by loss-of-function variants in Cellular Communication Network Factor 6 (CCN6, aka, WISP3). Patients with PPAC are asymptomatic at birth but develop polyarticular arthropathy in childhood, requiring multiple arthroplasties before 30 years of age. Currently, no therapy prevents or delays PPAC progression. Furthermore, how loss of CCN6 affects joint development or homeostasis is unknown due to the unavailability of pre-symptomatic patient tissue and the absence of a phenotype in Ccn6 knockout (KO) mice. CCN6-KO sheep were generated, anticipating that a larger and longer-lived animal would better model human PPAC. Juvenile KO sheep developed clinical signs of joint disease that worsened with age, and histologic examination of KO tissue revealed precocious cartilage damage. Additionally, KO cartilage differed from WT biomechanically, biochemically, and transcriptomically; with KO sheep cartilage sharing multiple transcriptomic features observed in cartilage derived from PPAC patient-induced pluripotent cell lines. These data indicate CCN6-KO sheep recapitulate clinical, histological, and molecular features of PPAC, and can be used to elucidate disease mechanisms and test therapies.

31 July 2025 in bioRxiv
Verified
Preprint
Open access
CDChristian D. DeMoya
Christian D. DeMoya
PHPierson Husted
Pierson Husted
DMDev R. Mehrotra
Dev R. Mehrotra
MAMichael B. Albro
Michael B. Albro
BSBrian D. Snyder
Brian D. Snyder
MGMark Grinstaff
Mark Grinstaff
Cartilage extracellular matrix (ECM) comprises a type-II collagen fibril network that affords structure and tensile strength, complemented by a negatively charged, sulfated glycosaminoglycan (GAG) matrix that retains interstitial water. These components act synergistically, bestowing the rheological and tribological material properties essential to cartilage function. At the onset of osteoarthritis, a disease characterized by cartilage degeneration, GAGs diminish from the ECM reducing interstitial fluid load support ( IFLS ) and transferring load to the collagen fibril network, which subsequently breaks down, culminating in increased hydraulic permeability, and decreased cartilage stiffness. We restore the material properties of damaged cartilage critical to diarthrodial joint function by forming an interpenetrating polymer network (IPN) with the native collagen using a synthetic, hydrophilic, and biocompatible GAG-mimetic polymer. Upon visible light activation, the monomer, 3-sulfopropylmethacrylate (SPM), and the crosslinker, polyethylene glycol diacrylate (PEGDA), form a sulfonated and anionic IPN that entangles and fills the existing porous degraded collagen matrix. Mechanistically, the highly sulfated, anionic SPM IPN retards water transport, reestablishes collagen fibril network integrity, and restores tissue IFLS , thereby returning the stiffness and viscoelastic properties of degraded cartilage to healthy levels. Additionally, the SPM IPN protects cartilage from further degradation by reducing the infiltration of inflammatory cytokines that upregulate catabolic matrix metalloproteinases and downregulate GAG production. Statement of significance: Amelioration of OA requires a comprehensive approach: neutralize or impede catabolic enzymes that degrade cartilage and reconstitute damaged cartilage by augmenting tissue ECM constituents. Currently, there are no clinical treatments that restore the viscoelastic material properties of hyaline cartilage tissue critical to its mechanical function and impart chondroprotection after OA induction. This work suggests that reconstituting GAG-depleted cartilage using a synthetic sulfonated interpenetrating polymer to reestablish IFLS that can be instilled into the joint and polymerized with white light during conventional arthroscopy represents a novel, minimally invasive, clinical treatment for early OA.